查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1159342

週期蛋白依賴型激梅(CDK)抑制劑的全球市場(2022年～2028年)

Cyclin Dependent Kinase (CDK) Inhibitors Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 125 Pages | 商品交期: 2-3個工作天內

價格

全球週期蛋白依賴型激梅(CDK)抑制劑的市場規模在預測期間內預計將以相當的年複合成長率成長。推動這個市場的主要原因有全球癌症的盛行率上升等。

本報告提供全球週期蛋白依賴型激梅(CDK)抑制劑市場調查，提供市場概要，市場的推動因素與阻礙因素的分析，市場機會，各市場區隔，各地區的市場分析，主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • Beta Pharma, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • Eli Lilly and Co.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • FLX Bio Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • G1 Therapeutics Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • Jiangsu Hengrui Medicine Co. Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析
  • COVID-19對主要企業帶來的影響

第4章 市場區隔

  • 各類型
    • 特定抑制劑
    • 非特異性抑制劑(廣域抑制劑)
    • 複數標的抑制劑
  • 給藥
    • 鼻子
    • 口服
    • 靜脈內
    • 肌肉內
  • 各用途
    • 乳癌
    • 淋巴瘤
    • 多發性骨髓瘤
    • 卵巢癌症
    • 其他(囊狀纖維化症)

第5章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他的亞太地區
  • 全球其他地區

第6章 企業簡介

  • Novartis Pharma AG
  • Onconova Therapeutics, Inc.
  • Pfizer Inc.
  • Teijin Ltd.
  • ViroStatics srl
  • Xuanzhu Biopharmaceutical Co., Ltd.
Product Code: OMR2026465

Global Cyclin Dependent Kinase (CDK) Inhibitors Market Size, Share & Trends Analysis Report by Type (Specific Inhibitors, Non-Specific Inhibitors, and Multiple Target Inhibitors), by Administration (Nasal, Oral, Intravenous, and Intramuscular), and by Application (Breast Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, And Others) Forecast Period 2022-2028

The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a substantial CAGR during the forecast period. One of the major factors driving the CDK inhibitors market is the rising prevalence of cancer across the globe. According to the World Health Organization (WHO), globally around 10 million deaths were reported which were caused due to cancer in 2020. In addition, the presence of a robust clinical pipeline due to the high demand for novel drugs and therapies is another factor propelling the growth of the market. Thus, market players are inclined toward launching novel CDK inhibitors to cater to the rising demand. For instance, in August 2020, ARC Therapeutic developed CDK inhibitors for treating advanced and resistant cancers. Currently, three CDK4/6 inhibitors including drugs such as Palbociclib, ribociclib, and abemaciclib have been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer by USFDA.

The global cyclin dependent kinase (CDK) inhibitors market is segmented based on the type, administration, and application. Based on the type, the market is segmented into specific inhibitors, non-specific or broad-range inhibitors, and multiple target inhibitors. Based on the administration, the market is sub-segmented into the nasal, oral, intravenous, and intramuscular. Based on application, the market is sub-segmented into breast cancer, lymphoma, multiple myeloma, ovarian cancer, and others. Among the administration segment, the oral sub-segment is expected to hold a considerable market share of the CDK inhibitors market over the forecast period, owing to the rising various R&D activities. For instance, in October 2021, the USFDA approved Verzenio in combination with endocrine therapy. Verzenio had been developed by Eli Lilly and Co. for treating HR+ HER2- early breast cancer. It is a non-chemotherapy oral tablet.

Geographically the global cyclin dependent kinase (CDK) inhibitors market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among all the regions, North America is expected to hold a prominent share of the CDK inhibitors market during the forecast period, followed by Europe. The primary factor contributing to the regional growth includes the rising prevalence of cancer in the countries such as the US and Canada. According to the Canadian Cancer Society, in 2021, approximately 46% of the total Canadian population were diagnosed with cancer. Lung, breast, prostate, colorectal cancers are expected to remain the most commonly diagnosed cancer.

The major companies serving the global cyclin dependent kinase (CDK) inhibitors market include Beta Pharma, Inc., Eli Lilly & Co., FLX Bio, Inc., G1 Therapeutics Inc., Novartis Pharma AG, and Pfizer Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PilmoSIM Therapeutics strategically collaborated with investigators from National Jewish Health and Brown University for the clinical development of PT001. To provide curative treatment, this drug targets multiple responsible pathways in PAH.

Research Methodology

The market study of the global cyclin dependent kinase (CDK) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Type.

2. Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Administration.

3. Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Application.

The Report Covers:

  • Comprehensive Research Methodology of the global cyclin dependent kinase (CDK) inhibitors market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global cyclin dependent kinase (CDK) inhibitors market.
  • Insights about market determinants that are stimulating the global cyclin dependent kinase (CDK) inhibitors market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Cyclin Dependent Kinase (CDK) Inhibitors Market
  • Recovery Scenario of Global Cyclin Dependent Kinase (CDK) Inhibitors Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Beta Pharma, Inc.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Eli Lilly and Co.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. FLX Bio Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. G1 Therapeutics Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Jiangsu Hengrui Medicine Co. Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Type
    • 4.1.1. Specific Inhibitors
    • 4.1.2. Non-Specific Inhibitors (Broad Range Inhibitors)
    • 4.1.3. Multiple Target Inhibitors
  • 4.2. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Administration
    • 4.2.1. Nasal
    • 4.2.2. Oral
    • 4.2.3. Intravenous
    • 4.2.4. Intramuscular
  • 4.3. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Application
    • 4.3.1. Breast Cancer
    • 4.3.2. Lymphoma
    • 4.3.3. Multiple Myeloma
    • 4.3.4. Ovarian Cancer
    • 4.3.5. Others (Cystic Fibrosis)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Novartis Pharma AG
  • 6.2. Onconova Therapeutics, Inc.
  • 6.3. Pfizer Inc.
  • 6.4. Teijin Ltd.
  • 6.5. ViroStatics srl
  • 6.6. Xuanzhu Biopharmaceutical Co., Ltd.

LIST OF TABLES

  • 1. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL NON-SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL MULTIPLE TARGET CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 6. GLOBAL NASAL FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL ORAL FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL INTRAVENOUS FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL INTRAMUSCULAR FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 11. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OVARIAN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 27. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
  • 32. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET, 2022-2028 (%)
  • 4. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL NON-SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL MULTIPLE TARGET CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY ADMINISTRATION, 2021 VS 2028 (%)
  • 9. GLOBAL NASAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL ORAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL INTRAVENOUS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL INTRAMUSCULAR CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 14. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR BREAST CANCER DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR LYMPHOMA DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR MULTIPLE MYELOMA DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OVARIAN CANCER DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OTHERS DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. US CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. CANADA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. UK CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. FRANCE CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. GERMANY CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. ITALY CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SPAIN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF EUROPE CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. INDIA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. CHINA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. JAPAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. SOUTH KOREA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)